Hematology

Hematology
No.Study TitlePrinciple InvestigatorSponsorTypeRecruitingStudy status
1REACH 3 study: A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with  corticosteroid-refractory chronic graft vs host disease after allogenic stem cell transplantation.Dr. Husam Abu JazarNovartisClinical TrialNo Ongoing
2Safety and Efficacy of Dasatinib 50 mg in First Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia.Dr. Kamal Al-RabiHikmaClinical TrialYesOngoing
3A phase II, open-label, single arm study to evaluate the safety, efficacy, and pharmacokinetics of twice daily midostaurin (PKC412) combined with standard chemotherapy and as a single agent post-consolidation therapy in children with untreated FLT3-mutated AML.Dr. Mayada Abu ShanabNovartisClinical TrialNoPending